Immunovant, Inc. Common Stock

IMVT US45258J1025

💰
Capitalization
Mid-cap

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

🔗
Website
https://www.immunovant.com
Annual Performance 1
2021 2022 2023 2024 2025
-81% 102% 125% -40% -2%
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
144
🙍
Insiders
12
Person Price Shares Total Published Completed
Geffner Michael
CMO 		18.15
USD 		2,385
Sold 		43,288
USD 		23/07/2025 23/07/2025
Stout Jay S
CTO 		18.15
USD 		2,805
Sold 		50,911
USD 		23/07/2025 23/07/2025
Geffner Michael
CMO 		17.24
USD 		1,160
Sold 		19,998
USD 		09/07/2025 09/07/2025
Stout Jay S
CTO 		17.24
USD 		1,519
Sold 		26,188
USD 		09/07/2025 09/07/2025
Geffner Michael
CMO 		14.79
USD 		2,349
Sold 		34,742
USD 		23/04/2025 23/04/2025
Stout Jay S
CTO 		14.79
USD 		1,925
Sold 		28,471
USD 		23/04/2025 23/04/2025
Barnett Eva Renee
CFO 		14.89
USD 		2,993
Sold 		44,566
USD 		16/04/2025 16/04/2025
Salzmann Peter
CEO 		14.89
USD 		8,321
Sold 		123,900
USD 		16/04/2025 16/04/2025
Geffner Michael
CMO 		12.99
USD 		6,169
Sold 		80,135
USD 		09/04/2025 09/04/2025
Barnett Eva Renee
CFO 		12.99
USD 		4,050
Sold 		52,610
USD 		09/04/2025 09/04/2025

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include Immunovant, Inc. Common Stock to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Historical Performance
1M 3M 6M 1Y 3Y 5Y All Time
-19% -15% -25% 32% 10% 0% 149%
Last 52W Low 52W High All-Time Low All-Time High β
16.08 13.31 31.42 3.38 52.71
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Roivant Sciences Ltd. 1 336,900,200.00 336,900,200.00 13/01/2025 13/01/2025
Salzmann Peter 32 7,923,338.91 247,604.34 22/11/2023 16/04/2025
Barnett Eva Renee 24 2,076,409.08 86,517.04 22/11/2023 16/04/2025
Butchko Julia G. 16 1,401,381.22 87,586.33 22/11/2023 21/08/2024
Levine Mark S. 17 1,389,557.37 81,738.67 22/11/2023 20/11/2024
Macias William L. 23 1,005,174.41 43,703.24 22/11/2023 19/02/2025
Geffner Michael 10 908,205.96 90,820.60 26/01/2024 23/07/2025
Pande Atul 4 711,852.50 177,963.13 01/12/2023 02/12/2024
Fromkin Andrew J. 5 647,465.68 129,493.14 01/12/2023 07/03/2025
Stout Jay S 8 590,559.25 73,819.91 24/04/2024 23/07/2025
Migausky George V 3 504,567.30 168,189.10 01/12/2023 01/12/2023
Hughes Douglas J. 1 154,829.50 154,829.50 02/12/2024 02/12/2024

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.